Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

Witzig, T.; Tobinai, K.; Rigacci, L.; Ikeda, T.; Vanazzi, A.; Hino, M.; Shi, Y.; Mayer, J.; Costa, L.; Bermudez Silva, C.; Zhu, J.; Belada, D.; Bouabdallah, K.; Kattan, J.; Kuruvilla, J.; Kim, W.; Larouche, J-F; Ogura, M.; Ozcan, M.; Fayad, L.; Wu, C.; Fan, J.; Louveau, A-L; Voi, M.; Cavalli, F.

doi:10.1093/annonc/mdx764

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

Witzig T. E., Tobinai K., Rigacci L., Ikeda T., Vanazzi A., Hino M., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.29, sa.3, ss.707-714, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 29 Sayı: 3
Basım Tarihi: 2018
Doi Numarası: 10.1093/annonc/mdx764
Dergi Adı: ANNALS OF ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.707-714
Anahtar Kelimeler: Adjuvant therapy, everolimus, large cell lymphoma, R-CHOP, MAINTENANCE RITUXIMAB, ELDERLY-PATIENTS, OLDER PATIENTS, CYCLOPHOSPHAMIDE, MULTICENTER, VINCRISTINE, DOXORUBICIN, REMISSION, PLACEBO
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Ankara Üniversitesi Adresli: Evet

Özet

Patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) a parts per thousand 3 are at higher risk for relapse after a complete response (CR) to first-line rituximab-based chemotherapy (R-chemo). Everolimus has single-agent activity in lymphoma. PILLAR-2 aimed to improve disease-free survival (DFS) with 1 year of adjuvant everolimus.